Risk assessment for prolonged sickness absence due to musculoskeletal disorders: protocol for a prospective cohort study.


Journal

BMC musculoskeletal disorders
ISSN: 1471-2474
Titre abrégé: BMC Musculoskelet Disord
Pays: England
ID NLM: 100968565

Informations de publication

Date de publication:
25 May 2020
Historique:
received: 21 02 2020
accepted: 19 05 2020
entrez: 27 5 2020
pubmed: 27 5 2020
medline: 12 2 2021
Statut: epublish

Résumé

Musculoskeletal disorders are the leading cause of sickness absence and disability pension in Norway. There is strong evidence that long-term sickness absence due to musculoskeletal disorders are associated with a reduced probability of return to work (RTW). A way to meet the economic and resource-demanding challenges related to individual follow-up of this group is to identify and treat those individuals with a high risk of prolonged sickness. The overall purposes of this project are 1) to determine the most accurate screening tool to identify people at a high risk of prolonged sickness absence due to an musculoskeletal disorder, and 2) to investigate severity of musculoskeletal health, health-related quality-of-life, health care utilization, and costs across different risk profiles in people on sick leave due to a musculoskeletal disorder. People older than 18 years of age on sick leave for at least 4 weeks due to a musculoskeletal disorder will be invited to participate in this prospective observational cohort study conducted within the Norwegian Welfare and Labor Administration (NAV) system in collaboration with OsloMet - Oslo Metropolitan University. The main outcome is sickness absence, obtained from the NAV registry. Data on sickness absence will be retrieved prospectively in the period from study inclusion to 12 months follow-up, and retrospectively 12 months before inclusion in the study. Possible risk factors will be self-reported by the participants at inclusion while health care utilization will be retrieved from registry data. To conduct analyses including 15 to 20 predictor variables, we aim at including 500-600 people on sick leave due to musculoskeletal disorders. This study may provide tools that can be used to identify individuals with high risk of prolonged sickness absence and may thus be important from both a socioeconomic and individual perspective. Further, the study may give valuable insight into identification of sickness absence profiles and the associations between these profiles and musculoskeletal health status, health-related quality of life and costs. Retrospectively registered in ClinicalTrials.gov (NCT04196634, 27.11.2019).

Sections du résumé

BACKGROUND BACKGROUND
Musculoskeletal disorders are the leading cause of sickness absence and disability pension in Norway. There is strong evidence that long-term sickness absence due to musculoskeletal disorders are associated with a reduced probability of return to work (RTW). A way to meet the economic and resource-demanding challenges related to individual follow-up of this group is to identify and treat those individuals with a high risk of prolonged sickness. The overall purposes of this project are 1) to determine the most accurate screening tool to identify people at a high risk of prolonged sickness absence due to an musculoskeletal disorder, and 2) to investigate severity of musculoskeletal health, health-related quality-of-life, health care utilization, and costs across different risk profiles in people on sick leave due to a musculoskeletal disorder.
METHODS METHODS
People older than 18 years of age on sick leave for at least 4 weeks due to a musculoskeletal disorder will be invited to participate in this prospective observational cohort study conducted within the Norwegian Welfare and Labor Administration (NAV) system in collaboration with OsloMet - Oslo Metropolitan University. The main outcome is sickness absence, obtained from the NAV registry. Data on sickness absence will be retrieved prospectively in the period from study inclusion to 12 months follow-up, and retrospectively 12 months before inclusion in the study. Possible risk factors will be self-reported by the participants at inclusion while health care utilization will be retrieved from registry data. To conduct analyses including 15 to 20 predictor variables, we aim at including 500-600 people on sick leave due to musculoskeletal disorders.
DISCUSSION CONCLUSIONS
This study may provide tools that can be used to identify individuals with high risk of prolonged sickness absence and may thus be important from both a socioeconomic and individual perspective. Further, the study may give valuable insight into identification of sickness absence profiles and the associations between these profiles and musculoskeletal health status, health-related quality of life and costs.
TRIAL REGISTRATION BACKGROUND
Retrospectively registered in ClinicalTrials.gov (NCT04196634, 27.11.2019).

Identifiants

pubmed: 32450820
doi: 10.1186/s12891-020-03354-7
pii: 10.1186/s12891-020-03354-7
pmc: PMC7249352
doi:

Banques de données

ClinicalTrials.gov
['NCT04196634']

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

326

Subventions

Organisme : Norges Forskningsråd
ID : 280431

Références

J Occup Rehabil. 2019 Jun;29(2):295-302
pubmed: 29796980
J Pain Res. 2016 Oct 14;9:807-818
pubmed: 27789972
Lancet. 2016 Oct 8;388(10053):1545-1602
pubmed: 27733282
J Clin Epidemiol. 2010 Jul;63(7):737-45
pubmed: 20494804
BMJ Open. 2016 Aug 05;6(8):e012331
pubmed: 27496243
Spine (Phila Pa 1976). 1998 Oct 1;23(19):2091-5
pubmed: 9794053
Arthritis Rheum. 2008 May 15;59(5):632-41
pubmed: 18438893
Qual Life Res. 2011 Dec;20(10):1727-36
pubmed: 21479777
Lancet. 2011 Oct 29;378(9802):1560-71
pubmed: 21963002
J Occup Rehabil. 2019 Sep;29(3):475-482
pubmed: 30151631
Ann Rheum Dis. 2014 Jun;73(6):982-9
pubmed: 24550172
J Rehabil Med. 2018 Feb 13;50(2):193-199
pubmed: 29206274
Occup Med (Lond). 2001 Mar;51(2):124-35
pubmed: 11307688
Chiropr Man Therap. 2016 Sep 08;24(1):32
pubmed: 27610218
J Occup Rehabil. 2018 Mar;28(1):170-179
pubmed: 28401441
Spine (Phila Pa 1976). 2000 Dec 15;25(24):3186-91
pubmed: 11124735
BMC Musculoskelet Disord. 2014 May 24;15:176
pubmed: 24886568
BMC Public Health. 2013 Dec 24;13:1229
pubmed: 24365383
BMJ Open. 2016 Oct 14;6(10):e012445
pubmed: 27742627
BMC Public Health. 2018 Jun 18;18(1):756
pubmed: 29914463
Spine (Phila Pa 1976). 1998 Aug 15;23(16):1775-83; discussion 1783-4
pubmed: 9728378
Bull World Health Organ. 2003;81(9):646-56
pubmed: 14710506
Tidsskr Nor Laegeforen. 2010 Nov 4;130(21):2106
pubmed: 21052101
Spine (Phila Pa 1976). 2011 Oct 15;36(22):1891-5
pubmed: 21192286
Value Health. 2014 Nov;17(7):A550
pubmed: 27201788

Auteurs

Anne Therese Tveter (AT)

Department of Physiotherapy, Faculty of Health Sciences, Oslo Metropolitan University, St.Olavs plass, 0130, Oslo, Norway. anthtv@oslomet.no.
National Advisory Unit on Rehabilitation in Rheumatology, Division of Rheumatology and Research, Diakonhjemmet Hospital, Oslo, Norway. anthtv@oslomet.no.

Britt Elin Øiestad (BE)

Department of Physiotherapy, Faculty of Health Sciences, Oslo Metropolitan University, St.Olavs plass, 0130, Oslo, Norway.

Tarjei Langseth Rysstad (TL)

Department of Physiotherapy, Faculty of Health Sciences, Oslo Metropolitan University, St.Olavs plass, 0130, Oslo, Norway.

Fiona Aanesen (F)

Department of Physiotherapy, Faculty of Health Sciences, Oslo Metropolitan University, St.Olavs plass, 0130, Oslo, Norway.

Alexander Tingulstad (A)

Department of Physiotherapy, Faculty of Health Sciences, Oslo Metropolitan University, St.Olavs plass, 0130, Oslo, Norway.

Milada Cvancarova Småstuen (MC)

Department of Nursing and Health Promotion, Faculty of Health Sciences, Oslo Metropolitan University, Oslo, Norway.

Margreth Grotle (M)

Department of Physiotherapy, Faculty of Health Sciences, Oslo Metropolitan University, St.Olavs plass, 0130, Oslo, Norway.
Research and Communication Unit for Musculoskeletal Health (FORMI), Oslo University Hospital, Oslo, Norway.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH